Chinook_yahoo_711x400.jpg
Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
February 07, 2023 16:05 ET | Chinook Therapeutics, Inc.
SEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook_yahoo_711x400.jpg
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023 16:05 ET | Chinook Therapeutics, Inc.
SEATTLE, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook_yahoo_711x400.jpg
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:00 ET | Chinook Therapeutics, Inc.
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook_yahoo_711x400.jpg
Chinook Therapeutics to Present at Upcoming Investor Conferences
November 22, 2022 16:05 ET | Chinook Therapeutics, Inc.
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook_yahoo_711x400.jpg
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 10, 2022 16:00 ET | Chinook Therapeutics, Inc.
SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
BION-1301 Treatment Results in Rapid and Durable Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
November 04, 2022 10:00 ET | Chinook Therapeutics, Inc.
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is...
Atrasentan Treatment Results in Clinically Meaningful Proteinuria Reductions in Patients with IgAN
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
November 03, 2022 10:00 ET | Chinook Therapeutics, Inc.
Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12...
Chinook_yahoo_711x400.jpg
Chinook Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022 16:00 ET | Chinook Therapeutics, Inc.
SEATTLE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
chinook_logo.jpg
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
October 14, 2022 08:00 ET | Chinook Therapeutics, Inc.
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the...
Chinook Logo.png
Chinook Therapeutics to Present at Upcoming Investor Conferences
September 01, 2022 16:05 ET | Chinook Therapeutics, Inc.
SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...